$0.53
4.54% yesterday
NYSE, Apr 04, 10:10 pm CET
ISIN
US9286611077
Symbol
VNRX
Sector

VolitionRX Stock News

Neutral
Seeking Alpha
4 days ago
VolitionRx Limited (NYSE:VNRX ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Cameron Reynolds - President & Chief Executive Officer Terig Hughes - Chief Financial Officer Andrew Retter - Chief Medical Officer Conference Call Participants Bruce Jackson - The Benchmark Company Ilya Zubkov - Freedom Brok...
Neutral
PRNewsWire
4 days ago
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada , March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024.
Neutral
PRNewsWire
8 days ago
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized  for the early identification of subjects at high risk of cancer HENDERSON, Nev. , March 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYS...
Neutral
PRNewsWire
9 days ago
HENDERSON, Nev. , March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and Dr. Jake Micallef, Chief Scientific Officer.
Neutral
PRNewsWire
10 days ago
Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev. , March 26, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announces today that it has entered into definitive agreements for the pur...
Neutral
PRNewsWire
11 days ago
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev.
Neutral
PRNewsWire
15 days ago
Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity HENDERSON, Nev. , March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in development detected a range of 21...
Neutral
PRNewsWire
16 days ago
"Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1 HENDERSON, Nev. , March 20, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung cancer primer, "Lung Cancer: Ho...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today